1. Scrip
  2. >>Business

Finance Watch: New Private Funding Available Across The Spectrum For Biopharma Firms

Despite Public Market Turmoil, Venture And Other Cash Is Flowing

 
• By Mandy Jackson

Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement. 

Finance Watch Image
• Source: Shutterstock

Venture capital investors are doubling down, placing new bets on drug developers even as the public markets are taking money off the table in the biopharmaceutical sector. For instance, Texas Medical Center recently doubled its TMC Venture Fund to $50m and three venture capital firms revealed new funds totaling more than $1.6bn during the first two and a half weeks of March.

Texas Medical Center announced the doubling of its fund on 14 March – two days before Frazier Life Sciences unveiled its new $987m fund. The TMC Venture Fund aims to help the city of Houston become a life science entrepreneurship hub. The fund launched with $25m in 2017 and has partnered with 16 start-ups, focusing on digital health and medical devices

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.